Social network
  • Visit We R Hope page

    We R Hope by Sanofi

  • Fighting dengue ferver

    Fighting dengue ferver

  • Meet Anne-Olivier Bandini: R&D Team Leader, France

  • Isabelle, Type 1 diabetes, France

    Isabelle, Type 1 diabetes, France

    Tools content (print, share, increase/decrease text size):

     

    R&D Portfolio

    At the end of April 2017, the R&D pipeline contained 46 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 13 are in Phase 3 or have been submitted to the regulatory authorities for approval.

     

    © Sanofi 2004-2017 - All rights reserved - Update: April 28, 2017

    • Site complies with W3C WCAG 2.0 (new window, in english)